Lupus (systemic lupus erythematosus, or SLE) and scleroderma (systemic sclerosis, or SSc) are distinct autoimmune diseases that can, in uncommon cases, appear together in the same person. A review of all reported cases from the 1990s through 2013 identified only about 101 patients with this particular overlap worldwide, making it a genuinely rare combination.1PubMed Central. Overlap Syndrome-Systemic Sclerosis, Systemic Lupus Erythematosus and Dermatomyositis – Case Report – Section: Discussion Despite that rarity, the two diseases share surprising genetic and immunological ground, and understanding the connection matters for anyone navigating a diagnosis that touches both.
Two Diseases, One Immune System Gone Wrong
SLE is best known for attacking joints, skin, kidneys, and blood cells in unpredictable flares. SSc, by contrast, is defined by progressive fibrosis, the hardening and thickening of skin and internal organs due to excess collagen. On paper, they look like different problems. But both arise from the same broad breakdown: the immune system turns on the body’s own tissues, producing autoantibodies, chronic inflammation, and damage to blood vessels. Research into the preclinical stages of both diseases shows that derangements in both the innate and adaptive immune system, along with chronic cytokine production, set the stage well before symptoms appear.2PubMed Central. Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue Diseases – Section: Abstract
A key molecular player in both diseases is transforming growth factor beta (TGF-β), a signaling molecule that regulates cell growth, programmed cell death, and the production of the structural matrix around cells. In scleroderma, TGF-β is a major driver of the runaway fibrosis that defines the disease.3PubMed Central. Transforming growth factor-β signaling in systemic sclerosis – Section: Abstract In lupus, the inflammatory cascade damages tissues differently, through immune complex deposition and complement activation, but the upstream immune dysfunction, including blood vessel injury and autoantibody production, overlaps substantially with what happens in SSc.
Macrophages, a type of immune cell that acts as both a first responder and a cleanup crew, also behave abnormally in both conditions. In SSc, macrophages drive fibrosis in the skin and lungs. In SLE, they contribute to kidney damage. The way these cells shift their behavior during disease progression is an active area of research, and the similarities across both diseases suggest shared pathways that future treatments could target.4Nature Reviews Rheumatology. Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases – Section: Abstract
Shared Genetic Risk
Genome-wide studies have revealed that lupus and scleroderma share multiple genetic susceptibility spots. A large pan-meta-analysis covering more than 21,000 individuals confirmed that the gene region KIAA0319L is a shared risk locus for both diseases, and established that two loci previously linked only to lupus, PXK and JAZF1, also increase susceptibility to scleroderma.5PubMed Central. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci – Section: Abstract A separate cross-disease analysis that also included rheumatoid arthritis and inflammatory myopathies identified five additional shared loci, including NAB1, KPNA4-ARL14, and LIMK1, that had not been previously linked to any of these diseases individually.6Annals of the Rheumatic Diseases. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases – Section: Abstract
This genetic overlap helps explain why some people develop features of both diseases, or why a person with one condition carries a higher-than-average risk for the other. But genetics is only part of the picture. Epigenetic modifications, changes in how genes are switched on or off without altering the DNA code itself, are influenced by environmental exposures, ethnicity, and aging. In scleroderma, the interplay between a person’s genetic susceptibility and these non-genetic factors is thought to determine whether and how the disease develops.7PubMed Central. Epigenetics of scleroderma: Integrating genetic, ethnic, age, and environmental effects Similar environmental triggers, including silica dust, organic solvents, and certain viral infections, have been implicated in both lupus and scleroderma, which makes the overlap less surprising once you look beneath the surface.
The Interferon Connection
One of the most striking biological similarities between lupus and scleroderma is the activation of the type I interferon pathway. Interferons are proteins the body normally releases to fight viruses. In autoimmune disease, that system fires inappropriately, fueling chronic inflammation. Lupus has long been known as a disease driven in part by interferon overactivity. More recently, research has shown that the role of type I interferon in scleroderma is becoming increasingly evident and strikingly similar to the role observed in lupus.8PubMed Central. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit – Section: Abstract
A study examining blood and tissue samples from patients with lupus, scleroderma, rheumatoid arthritis, and inflammatory muscle disease found a common set of 36 interferon-inducible genes overexpressed across all groups. The interferon gene signature correlated with disease activity in lupus and scleroderma patients alike, and it was also well correlated between disease-affected tissue and blood samples in both conditions.9Annals of the Rheumatic Diseases. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway – Section: Results This shared interferon signature is more than an academic curiosity: it has become a therapeutic target. Drugs designed to block interferon signaling, already in development or use for lupus, are being explored for scleroderma as well.
When Both Appear Together
The lupus-scleroderma overlap is not simply “having two diseases at once.” In many cases, patients present with features of both without neatly meeting the full classification criteria for either. A person might have the skin tightening and Raynaud’s phenomenon typical of scleroderma alongside the joint inflammation, rashes, and blood cell abnormalities of lupus. This gray zone is sometimes categorized as an overlap syndrome or, when accompanied by high levels of anti-U1-ribonucleoprotein (anti-U1-RNP) antibodies, as mixed connective tissue disease (MCTD).
Anti-U1-RNP antibodies are strongly associated with overlap syndromes in which lupus features are accompanied by scleroderma or muscle inflammation.10PubMed. Overlap syndromes and mixed connective tissue disease Whether MCTD is a truly separate entity or just a transitional phase between lupus and scleroderma remains debated among rheumatologists. Some patients initially labeled with MCTD eventually evolve into a picture dominated by one disease. Others maintain mixed features indefinitely. For the person living with the condition, the label matters less than the specific organs involved and the treatment approach chosen.
Compared to patients with scleroderma alone, those with overlap syndromes tend to be younger at diagnosis, are less likely to carry anti-topoisomerase I (anti-Scl-70) antibodies, and typically require higher doses of steroids and immunosuppressive drugs during follow-up.11PubMed. Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma – Section: RESULTS
Autoantibodies and What They Reveal
Autoantibodies are a cornerstone of diagnosing and distinguishing autoimmune diseases, but they complicate matters when lupus and scleroderma overlap. Antibodies traditionally “belonging” to one disease frequently show up in patients with the other. A study of scleroderma overlap syndrome patients found that anti-Ro-52 was the most common antibody in the group, followed by anti-centromere antibody and anti-Scl-70.12PubMed Central. Autoantibodies in systemic sclerosis overlap syndrome and their correlation with organ damage and survival – Section: RESULTS Anti-Ro-52 is more commonly associated with lupus and Sjögren’s syndrome, so its prominence in SSc overlap patients illustrates how blurred the serological boundaries are.
Research directly comparing SSc-associated autoantibody profiles across lupus, Sjögren’s syndrome, and scleroderma has found that the 13 antibody specificities commonly tested for in SSc are also frequent among individuals with other interferon-driven diseases. In lupus patients specifically, associations between scleroderma-related autoantibodies and clinical manifestations were identified that had not been previously reported.13RMD Open. Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation – Section: Results This means that a positive result for a “scleroderma antibody” on a blood test does not automatically mean a lupus patient is developing scleroderma. It requires clinical context.
Ethnicity also plays a role. Among African American scleroderma patients, anti-topoisomerase I antibodies and anti-U1-RNP antibodies frequently coexist. When both antibodies were present, half of those patients had an overlap with lupus, compared to none of the patients who had anti-topoisomerase I alone.14PubMed Central. Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study – Section: Results This finding has practical diagnostic value: the combination of these two antibodies in a patient, particularly an African American patient, should prompt a careful evaluation for lupus features.
Clues Under a Microscope
One useful diagnostic tool is nailfold capillaroscopy, a non-invasive technique where a clinician looks at the tiny blood vessels at the base of the fingernails under magnification. In scleroderma, a distinctive “scleroderma pattern” of giant capillaries, capillary dropout, and bleeding is a well-established early sign. In lupus, the capillaroscopic picture is less specific and includes a wider range of abnormalities like tortuous, crossing, and elongated capillaries.15PubMed. Capillaroscopic pattern in systemic lupus erythematosus and undifferentiated connective tissue disease: what we still have to learn?
Interestingly, a small percentage of lupus patients without an obvious scleroderma diagnosis still show “scleroderma-like” capillary patterns, which is currently thought to reflect a potential subclinical overlap with SSc. A study of lupus patients found that giant capillaries, though uncommon overall at about 6% of the group, appeared specifically in patients with severe disease activity, supporting previous research linking these patterns to scleroderma-like features in severe lupus cases.16ReumatologÃa ClÃnica. Nailfold capillaroscopy changes in systemic lupus erythematosus patients: Correlation with disease activity and anti-uridin1-ribonucleoprotein antibodies – Section: Results For clinicians, this means capillaroscopy can serve as an early warning system for overlap features in lupus patients, particularly those with Raynaud’s phenomenon or anti-U1-RNP antibodies.
Organ Involvement When Both Diseases Collide
The organs most at risk differ somewhat between pure lupus and pure scleroderma, but when they overlap, the picture becomes especially complex.
Kidneys
Kidney involvement is common in both diseases but attacks through different mechanisms. In lupus, kidney damage (lupus nephritis) results from immune complexes depositing in the kidney’s filtering structures, causing inflammation. In scleroderma, renal crisis is driven by damage to the blood vessel lining in the kidneys and activation of blood pressure regulation hormones. Both can cause protein and blood in the urine, which makes initial distinction challenging. Lupus nephritis may also present with excessive urination and foamy urine, while scleroderma renal crisis typically involves severe hypertension and rapidly declining kidney function.17PubMed Central. The dilemma: scleroderma renal crisis vs lupus nephritis in a patient with mixed connective tissue disorder – Section: Discussion In a patient with features of both diseases, sorting out which process is responsible, or whether both are occurring simultaneously, often requires a kidney biopsy. Treatment decisions hinge on the answer: lupus nephritis is treated with immunosuppressants, while scleroderma renal crisis is primarily managed with blood pressure medications, specifically ACE inhibitors. High-dose steroids, a mainstay of lupus nephritis treatment, can actually precipitate scleroderma renal crisis, making this distinction high-stakes.
Lungs
Pulmonary complications are a major concern in scleroderma, where interstitial lung disease (scarring of the lung tissue) and pulmonary arterial hypertension (elevated pressure in the blood vessels of the lungs) are leading causes of death. Lupus can also cause lung inflammation and, less commonly, interstitial lung disease. When both diseases are present, pulmonary involvement tends to be especially prominent. Case reports of scleroderma overlap syndrome describe patients presenting with interstitial lung disease, pulmonary fibrosis, and pulmonary hypertension simultaneously.18Journal of Taibah University Medical Sciences. Scleroderma overlap syndrome with interstitial lung disease and pulmonary artery hypertension – Section: Case report Routine lung function screening with pulmonary function tests and echocardiograms is standard practice for scleroderma patients, and that vigilance should extend to anyone with an overlap diagnosis.
How Skin Manifestations Differ
Skin changes are often the most visible feature of both diseases, and they look quite different in practice. Scleroderma’s hallmark is skin thickening and tightening. In the limited form, this affects the fingers, hands, face, and sometimes the neck, and is often accompanied by visible small blood vessels on the surface (telangiectasias) and calcium deposits under the skin. In the diffuse form, hardening extends to the trunk and upper arms. Microscopically, the skin shows collagen bundles packed tighter than normal, with sweat glands trapped in the fibrotic tissue.19Anais Brasileiros de Dermatologia. Skin manifestations associated with systemic diseases – Part I – Section: Scleroderma
Lupus skin involvement is more varied and inflammatory: the butterfly-shaped facial rash, photosensitive rashes, discoid lesions that can scar, and mouth ulcers. A person with overlap may have both tightened skin on the hands and a photosensitive rash on the face, which can initially puzzle clinicians who are looking for one clean diagnosis. Raynaud’s phenomenon, where fingers turn white and then blue in response to cold or stress, is nearly universal in scleroderma and occurs in roughly a third of lupus patients. Its presence in a lupus patient, particularly alongside any skin tightening, should raise the question of overlap.
Treatment Challenges
Managing a lupus-scleroderma overlap is more complex than treating either disease alone, because the therapies do not always align. Lupus is typically managed with antimalarials like hydroxychloroquine, immunosuppressants such as mycophenolate or azathioprine, and steroids during flares. Scleroderma treatment is more organ-specific: vasodilators for Raynaud’s and pulmonary hypertension, mycophenolate or nintedanib for lung fibrosis, and ACE inhibitors for renal crisis. There is overlap in the toolkit, particularly with mycophenolate, which benefits both lupus kidney disease and scleroderma lung disease.
Biologic therapies are increasingly relevant. Rituximab, which depletes B cells, and belimumab, which targets a B-cell survival factor, are used in lupus and have been explored in scleroderma as well. Tocilizumab, which blocks the inflammatory cytokine IL-6, is another option under investigation for both conditions.20PubMed Central. Biologic therapy for autoimmune diseases: an update The interferon pathway’s involvement in both diseases has also spurred development of anti-interferon drugs. Anifrolumab, already approved for lupus, blocks the receptor for type I interferons and is being studied in scleroderma. For overlap patients, a drug that addresses shared pathology could be especially appealing, though clinical trial data in this specific population remains limited.
Survival and Prognosis
One question that understandably weighs on patients with overlap is whether having both diseases worsens the outlook. A study comparing survival in patients with SSc-SLE overlap versus scleroderma alone found that those with the overlap actually had slightly better median survival, about 26 years compared to about 22 years for scleroderma alone, though this difference did not quite reach statistical significance. When adjusted for sex and scleroderma subtype, the survival difference between the groups essentially disappeared.21The Journal of Rheumatology. Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome – Section: Abstract The takeaway is cautiously reassuring: having lupus features on top of scleroderma does not appear to worsen survival in a dramatic way, and the overlap group may even fare slightly better, possibly because their scleroderma tends to be less fibrotic.
Pregnancy in Lupus-Scleroderma Overlap
Pregnancy in either lupus or scleroderma requires careful monitoring, and the combination raises the stakes. A prospective study of scleroderma pregnancies found that roughly a quarter of ongoing pregnancies had an adverse outcome, most commonly placental insufficiency complications like pre-eclampsia or fetal growth restriction. The disease itself worsened in about 40% of pregnancies, mainly during the postpartum period. Having the diffuse skin form of scleroderma or a history of skin blood vessel involvement roughly quadrupled the odds of disease progression, while the presence of anti-centromere antibodies appeared protective.22The Lancet Rheumatology. Pregnancy outcomes and maternal disease course in systemic sclerosis: a prospective cohort study from the French GR2 study – Section: Summary
Lupus adds its own pregnancy risks, including a higher chance of pre-eclampsia, preterm birth, and flares, particularly if the disease is active at conception or if antiphospholipid antibodies are present. For someone with features of both conditions, preconception counseling with a rheumatologist and a high-risk obstetrician is essential. The general recommendation is to plan pregnancies during periods of disease quiescence, ideally on medications known to be safe in pregnancy, and to monitor closely for blood pressure changes, kidney function, and fetal growth throughout.
Emerging Biomarkers for Distinguishing the Two
One practical challenge is distinguishing scleroderma from lupus early, before the clinical picture has fully declared itself. New biomarker research is exploring whether tiny fragments of genetic material circulating in the blood, called microRNAs, could help. A study analyzing circulating microRNA profiles found that a panel of 21 microRNAs could distinguish scleroderma from both healthy individuals and lupus patients with about 80% accuracy. The distinction between healthy controls and scleroderma patients was sharper, at around 95% accuracy, driven largely by a specific cluster of microRNAs. The difference between lupus and scleroderma was more subtle, relying on a different subset of microRNAs.23The Journal of Rheumatology. The circulating cell-free microRNA profile in systemic sclerosis is distinct from both healthy controls and systemic lupus erythematosus – Section: RESULTS This kind of blood-based test is not yet in routine clinical use, but it points toward a future where ambiguous early presentations could be sorted more quickly, sparing patients the months or years of diagnostic uncertainty that overlap syndromes often entail.